Pembrolizumab plus chemo before or around liver surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests whether pembrolizumab combined with gemcitabine and cisplatin given around the time of surgery can improve outcomes for people with high-risk, potentially operable intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help by strengthening the immune system while also treating the cancer with chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign informed consent before any study checks.
- You must be 18 or older.
- You must have confirmed bile duct cancer in the liver (intrahepatic cholangiocarcinoma) that doctors can measure on scans.
- Your cancer must be high-risk but still technically resectable (possible to remove), based on recent CT/MRI (and sometimes PET) and blood tests.
- Your body must be strong enough for treatment (ECOG performance status 0–1) and your blood counts and organ functions must be within required ranges.
- If you can become pregnant or someone can father a child, you must use effective birth control during the study and for a set time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (gemcitabine, cisplatin, S-1) given before surgery for patients with bile duct cancer that is high-risk for return or has come back within 6 months after a prior surgery. The goal is to see if this treatment can improve outcomes.
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests whether giving chemotherapy (gemcitabine and cisplatin) combined with immunotherapy (pembrolizumab) before and after surgery can improve outcomes compared to having surgery right away. It is for people with bile duct cancer that can be removed or is borderline removable.
This trial tests a combination of chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) with an immunotherapy (rilvegostomig) before and after surgery for intrahepatic cholangiocarcinoma that can be completely removed. It aims to see if this approach improves outcomes.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.